Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial

被引：0
|
作者：
Mendell, J. [1 ]
Shell, R. [1 ]
Lehman, K. [1 ]
McColly, M. [1 ]
Lowes, L. [1 ]
Alfano, L. [1 ]
Miller, N. [1 ]
Iammarino, M. [1 ]
Church, K. [1 ]
Ogrinc, F. [2 ]
Ouyang, H. [2 ]
Kernbauer, E. [2 ]
Shah, S. [2 ]
L'Italien, J. [2 ]
Sproule, D. [2 ]
Feltner, D. [2 ]
Al-Zaidy, S. [1 ]
机构：
[1] Nationwide Childrens Hosp, Columbus, OH USA
[2] AveXis Inc, Bannockburn, IL USA
来源：
NEUROMUSCULAR DISORDERS | 2019年 / 29卷
关键词：
D O I：
10.1016/j.nmd.2019.06.513
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.351
引用
收藏
页码：S184 / S184
页数：1
相关论文
共 50 条
  • [11] Intrathecal administration of onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA2): phase 1/2a study (STRONG)
    Finkel, R.
    Day, J.
    Darras, B.
    Kuntz, N.
    Connolly, A.
    Crawford, T.
    Butterfield, R.
    Shieh, P.
    Tennekoon, G.
    Iannaccone, S.
    Ogrinc, F.
    Kavanagh, S.
    Kernbauer, E.
    Whittle, J.
    L'Italien, J.
    Kaspar, B.
    Sproule, D.
    Spector, S.
    Feltner, D.
    Mendell, J.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S207 - S207
  • [12] Intrathecal Administration of Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 2 (SMA2): Phase 1/2a Study (STRONG)
    Finkel, R.
    Day, J.
    Darras, B.
    Kuntz, N.
    Connolly, A.
    Crawford, T.
    Butterfield, R.
    Shieh, P.
    Tennekoon, G.
    Iannaccone, S.
    Ogrinc, F.
    Kavanagh, S.
    Kernbauer, E.
    Whittle, J.
    L'Italien, J.
    Kaspar, B.
    Sproule, D.
    Spector, S.
    Feltner, D.
    Mendell, J.
    ANNALS OF NEUROLOGY, 2019, 86 : S30 - S30
  • [13] ONASEMNOGENE ABEPARVOVEC GENE-REPLACEMENT THERAPY (GRT) FOR SPINAL MUSCULAR ATROPHY TYPE 1 (SMA1): PRELIMINARY PULMONARY AND VENTILATORY FINDINGS FROM THE PHASE 3 STUDY (STR1VE)
    Shell, R.
    Day, J. W.
    Chiriboga, C. A.
    Crawford, T. O.
    Darras, B. T.
    Finkel, R. S.
    Connolly, A. M.
    Iannaccone, S. T.
    Kuntz, N. L.
    Pena, L. D. M.
    Shieh, P. B.
    Smith, E. C.
    Kausar, I.
    Schultz, M.
    Feltner, D. E.
    Ogrinc, F. G.
    Macek, T. A.
    Kernbauer, E.
    L'Italien, J.
    Sproule, D. M.
    Kaspar, B. K.
    Mendell, J. R.
    THORAX, 2019, 74 : A42 - A42
  • [14] Long-Term Follow-Up of Onasemnogene Abeparvovec Gene Therapy in Patients with Spinal Muscular Atrophy Type 1
    Mendell, Jerry
    Wigderson, Melissa
    Alecu, Iulian
    Yang, Lina
    Mehl, Lesa
    Connolly, Anne
    NEUROLOGY, 2023, 100 (17)
  • [15] Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) in Pre-symptomatic Spinal Muscular Atrophy (SMA)
    Schultz, M.
    Swoboda, K.
    Farrar, M.
    McMillan, H.
    Parsons, J.
    Kernbauer, E.
    Farrow, M.
    Ogrinc, F.
    Kavanagh, S.
    Feltner, D.
    McGill, B.
    Spector, S.
    L'Italien, J.
    Sproule, D.
    Strauss, K.
    ANNALS OF NEUROLOGY, 2019, 86 : S133 - S133
  • [16] Onasemnogene abeparvovec gene-replacement therapy (GRT) in pre-symptomatic spinal muscular atrophy (SMA)
    Schultz, M.
    Swoboda, K.
    Farrar, M.
    McMillan, H.
    Parsons, J.
    Kernbauer, E.
    Farrow, M.
    Ogrinc, F.
    Kavanagh, S.
    Feltner, D.
    McGill, B.
    Spector, S.
    L'Italien, J.
    Sproule, D.
    Strauss, K.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S183 - S183
  • [17] Long-term follow-up (LTFU) of onasemnogene abeparvovec gene therapy in spinal muscular atrophy (SMA)
    Mendell, J.
    Finkel, R.
    Mercuri, E.
    Strauss, K.
    Day, J.
    Kleyn, A.
    Chand, D.
    Tauscher-Wisniewski, S.
    Meriggioli, M.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S132 - S133
  • [18] Long-term Follow-up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA)
    Day, J.
    Mendell, J.
    Finkel, R.
    Mercuri, E.
    Strauss, K.
    Kleyn, A.
    Chand, D.
    Tauscher-Wisniewski, S.
    Meriggioli, M.
    ANNALS OF NEUROLOGY, 2021, 90 : S151 - S152
  • [19] Onasemnogene abeparvovec gene-replacement therapy (GRT) in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update
    Strauss, K. A.
    Swoboda, K. J.
    Farrar, M. A.
    McMillan, H. J.
    Parsons, J.
    Krueger, J. M.
    Iannaccone, S. T.
    Chiriboga, C. A.
    Kwon, J. M.
    Saito, K.
    Scoto, M.
    Baldinetti, F.
    Schultz, M.
    Kernbauer, E.
    Farrow, M.
    Ogrinc, F. G.
    Kavanagh, S.
    Feltner, D. E.
    McGill, B. E.
    Spector, S. A.
    L'Italien, J.
    Sproule, D. M.
    Muntoni, F.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [20] Long-Term Follow-Up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA)
    Mendell, Jerry
    Finkel, Richard
    Mercuri, Eugenio
    Strauss, Kevin
    Day, John
    Kleyn, Aaron
    Chand, Deepa
    Tauscher-Wisniewski, Sitra
    Meriggioli, Matthew
    NEUROLOGY, 2021, 96 (15)
12345